Biofrontera Inc.
BFRI
$0.86
$0.0121.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.54% | 18.53% | 1.30% | 34.05% | -9.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.54% | 18.53% | 1.30% | 34.05% | -9.40% |
| Cost of Revenue | -20.60% | -1.79% | 6.25% | 50.35% | -10.48% |
| Gross Profit | 40.15% | 39.38% | -3.97% | 18.14% | -8.20% |
| SG&A Expenses | -6.34% | -9.32% | -3.07% | -30.54% | 6.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.82% | -1.31% | 4.93% | -9.97% | 0.54% |
| Operating Income | 16.83% | 55.71% | -12.22% | 40.28% | -19.52% |
| Income Before Tax | 59.72% | -139.74% | 10.65% | 97.59% | -39.65% |
| Income Tax Expenses | -200.00% | 50.00% | 200.00% | 42.86% | -80.00% |
| Earnings from Continuing Operations | 59.73% | -139.59% | 10.61% | 97.39% | -39.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.73% | -139.59% | 10.61% | 97.39% | -39.57% |
| EBIT | 16.83% | 55.71% | -12.22% | 40.28% | -19.52% |
| EBITDA | 15.38% | 55.13% | -12.51% | 40.94% | -20.06% |
| EPS Basic | 83.56% | -111.20% | 78.84% | 99.30% | 48.58% |
| Normalized Basic EPS | 83.04% | 73.92% | 65.87% | 99.27% | -3.19% |
| EPS Diluted | 83.56% | -122.43% | 78.84% | 99.30% | 48.58% |
| Normalized Diluted EPS | 83.04% | 73.92% | 65.87% | 99.27% | -3.19% |
| Average Basic Shares Outstanding | 144.89% | 253.49% | 322.45% | 274.18% | 171.43% |
| Average Diluted Shares Outstanding | 144.89% | 253.49% | 322.45% | 274.18% | 171.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |